Tissue-type plasminogen activator mutants; recombinant genetic information coding therefor and process for preparing said mutants; their use and pharmaceutical compositions

摘要

The invention relates to tissue-type plasminogen activator (t-PA) mutants having improved binding charact­eristics towards fibrin. The binding of t-PA to fibrin is due to the kringle K2 domain and, to a lesser extent, to the finger domain F. The claimed mutants either comprise at least one K2 or at least one F domain and lack one or more other parts of the t-PA molecule, or comprise at least two K2 or F domains, or comprise at least one modified K2 or F domain having improved binding characteristics towards fibrin. The invention also relates to a process for preparing said mutants by genetic engineering and to the recombinant genetic information used therein. Further, the invention relates to the use of said mutants in therapy or imaging and to pharmaceutical compositions suitable therefor.